Name,title,geo_accession,status,submission_date,last_update_date,type,channel_count,source_name_ch1,organism_ch1,taxid_ch1,characteristics_ch1.0.tissue,characteristics_ch1.1.disease,characteristics_ch1.2.response to infliximab,characteristics_ch1.3.before or after first infliximab treatment,molecule_ch1,extract_protocol_ch1,label_ch1,label_protocol_ch1,hyb_protocol,scan_protocol,description,data_processing,platform_id,contact_name,contact_email,contact_laboratory,contact_department,contact_institute,contact_address,contact_city,contact_zip/postal_code,contact_country,supplementary_file,relation,series_id,data_row_count
GSM364627,CO1,GSM364627,Public on Nov 03 2009,Jan 26 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from control individual,Homo sapiens,9606,Colon,Control,Not applicable,Not applicable,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from control individual,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM364nnn/GSM364627/suppl/GSM364627.CEL.gz,Reanalyzed by: GSE119087,"GSE14580,GSE16879",54675
GSM364628,CO2,GSM364628,Public on Nov 03 2009,Jan 26 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from control individual,Homo sapiens,9606,Colon,Control,Not applicable,Not applicable,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from control individual,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM364nnn/GSM364628/suppl/GSM364628.CEL.gz,Reanalyzed by: GSE119087,"GSE14580,GSE16879",54675
GSM364629,CO3,GSM364629,Public on Nov 03 2009,Jan 26 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from control individual,Homo sapiens,9606,Colon,Control,Not applicable,Not applicable,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from control individual,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM364nnn/GSM364629/suppl/GSM364629.CEL.gz,Reanalyzed by: GSE119087,"GSE14580,GSE16879",54675
GSM364630,CO4,GSM364630,Public on Nov 03 2009,Jan 26 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from control individual,Homo sapiens,9606,Colon,Control,Not applicable,Not applicable,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from control individual,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM364nnn/GSM364630/suppl/GSM364630.CEL.gz,Reanalyzed by: GSE119087,"GSE14580,GSE16879",54675
GSM364631,CO5,GSM364631,Public on Nov 03 2009,Jan 26 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from control individual,Homo sapiens,9606,Colon,Control,Not applicable,Not applicable,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from control individual,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM364nnn/GSM364631/suppl/GSM364631.CEL.gz,Reanalyzed by: GSE119087,"GSE14580,GSE16879",54675
GSM364632,CO6,GSM364632,Public on Nov 03 2009,Jan 26 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from control individual,Homo sapiens,9606,Colon,Control,Not applicable,Not applicable,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from control individual,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM364nnn/GSM364632/suppl/GSM364632.CEL.gz,Reanalyzed by: GSE119087,"GSE14580,GSE16879",54675
GSM364633,UCR1_beforeT,GSM364633,Public on Nov 03 2009,Jan 26 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from UC responder before first infliximab treatment,Homo sapiens,9606,Colon,UC,Yes,Before first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from UC responder before first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM364nnn/GSM364633/suppl/GSM364633.CEL.gz,Reanalyzed by: GSE119087,"GSE14580,GSE16879",54675
GSM364634,UCR2_beforeT,GSM364634,Public on Nov 03 2009,Jan 26 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from UC responder before first infliximab treatment,Homo sapiens,9606,Colon,UC,Yes,Before first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from UC responder before first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM364nnn/GSM364634/suppl/GSM364634.CEL.gz,Reanalyzed by: GSE119087,"GSE14580,GSE16879",54675
GSM364635,UCR3_beforeT,GSM364635,Public on Nov 03 2009,Jan 26 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from UC responder before first infliximab treatment,Homo sapiens,9606,Colon,UC,Yes,Before first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from UC responder before first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM364nnn/GSM364635/suppl/GSM364635.CEL.gz,Reanalyzed by: GSE119087,"GSE14580,GSE16879",54675
GSM364636,UCR4_beforeT,GSM364636,Public on Nov 03 2009,Jan 26 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from UC responder before first infliximab treatment,Homo sapiens,9606,Colon,UC,Yes,Before first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from UC responder before first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM364nnn/GSM364636/suppl/GSM364636.CEL.gz,Reanalyzed by: GSE119087,"GSE14580,GSE16879",54675
GSM364637,UCR5_beforeT,GSM364637,Public on Nov 03 2009,Jan 26 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from UC responder before first infliximab treatment,Homo sapiens,9606,Colon,UC,Yes,Before first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from UC responder before first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM364nnn/GSM364637/suppl/GSM364637.CEL.gz,Reanalyzed by: GSE119087,"GSE14580,GSE16879",54675
GSM364638,UCR6_beforeT,GSM364638,Public on Nov 03 2009,Jan 26 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from UC responder before first infliximab treatment,Homo sapiens,9606,Colon,UC,Yes,Before first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from UC responder before first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM364nnn/GSM364638/suppl/GSM364638.CEL.gz,Reanalyzed by: GSE119087,"GSE14580,GSE16879",54675
GSM364639,UCR7_beforeT,GSM364639,Public on Nov 03 2009,Jan 26 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from UC responder before first infliximab treatment,Homo sapiens,9606,Colon,UC,Yes,Before first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from UC responder before first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM364nnn/GSM364639/suppl/GSM364639.CEL.gz,Reanalyzed by: GSE119087,"GSE14580,GSE16879",54675
GSM364640,UCR8_beforeT,GSM364640,Public on Nov 03 2009,Jan 26 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from UC responder before first infliximab treatment,Homo sapiens,9606,Colon,UC,Yes,Before first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from UC responder before first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM364nnn/GSM364640/suppl/GSM364640.CEL.gz,Reanalyzed by: GSE119087,"GSE14580,GSE16879",54675
GSM364641,UCNR1_beforeT,GSM364641,Public on Nov 03 2009,Jan 26 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from UC non-responder before first infliximab treatment,Homo sapiens,9606,Colon,UC,No,Before first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from UC non-responder before first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM364nnn/GSM364641/suppl/GSM364641.CEL.gz,Reanalyzed by: GSE119087,"GSE14580,GSE16879",54675
GSM364642,UCNR2_beforeT,GSM364642,Public on Nov 03 2009,Jan 26 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from UC non-responder before first infliximab treatment,Homo sapiens,9606,Colon,UC,No,Before first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from UC non-responder before first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM364nnn/GSM364642/suppl/GSM364642.CEL.gz,Reanalyzed by: GSE119087,"GSE14580,GSE16879",54675
GSM364643,UCNR3_beforeT,GSM364643,Public on Nov 03 2009,Jan 26 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from UC non-responder before first infliximab treatment,Homo sapiens,9606,Colon,UC,No,Before first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from UC non-responder before first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM364nnn/GSM364643/suppl/GSM364643.CEL.gz,Reanalyzed by: GSE119087,"GSE14580,GSE16879",54675
GSM364644,UCNR4_beforeT,GSM364644,Public on Nov 03 2009,Jan 26 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from UC non-responder before first infliximab treatment,Homo sapiens,9606,Colon,UC,No,Before first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from UC non-responder before first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM364nnn/GSM364644/suppl/GSM364644.CEL.gz,Reanalyzed by: GSE119087,"GSE14580,GSE16879",54675
GSM364645,UCNR5_beforeT,GSM364645,Public on Nov 03 2009,Jan 26 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from UC non-responder before first infliximab treatment,Homo sapiens,9606,Colon,UC,No,Before first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from UC non-responder before first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM364nnn/GSM364645/suppl/GSM364645.CEL.gz,Reanalyzed by: GSE119087,"GSE14580,GSE16879",54675
GSM364646,UCNR6_beforeT,GSM364646,Public on Nov 03 2009,Jan 26 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from UC non-responder before first infliximab treatment,Homo sapiens,9606,Colon,UC,No,Before first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from UC non-responder before first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM364nnn/GSM364646/suppl/GSM364646.CEL.gz,Reanalyzed by: GSE119087,"GSE14580,GSE16879",54675
GSM364647,UCNR7_beforeT,GSM364647,Public on Nov 03 2009,Jan 26 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from UC non-responder before first infliximab treatment,Homo sapiens,9606,Colon,UC,No,Before first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from UC non-responder before first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM364nnn/GSM364647/suppl/GSM364647.CEL.gz,Reanalyzed by: GSE119087,"GSE14580,GSE16879",54675
GSM364648,UCNR8_beforeT,GSM364648,Public on Nov 03 2009,Jan 26 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from UC non-responder before first infliximab treatment,Homo sapiens,9606,Colon,UC,No,Before first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from UC non-responder before first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM364nnn/GSM364648/suppl/GSM364648.CEL.gz,Reanalyzed by: GSE119087,"GSE14580,GSE16879",54675
GSM364649,UCNR9_beforeT,GSM364649,Public on Nov 03 2009,Jan 26 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from UC non-responder before first infliximab treatment,Homo sapiens,9606,Colon,UC,No,Before first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from UC non-responder before first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM364nnn/GSM364649/suppl/GSM364649.CEL.gz,Reanalyzed by: GSE119087,"GSE14580,GSE16879",54675
GSM364650,UCNR10_beforeT,GSM364650,Public on Nov 03 2009,Jan 26 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from UC non-responder before first infliximab treatment,Homo sapiens,9606,Colon,UC,No,Before first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from UC non-responder before first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM364nnn/GSM364650/suppl/GSM364650.CEL.gz,Reanalyzed by: GSE119087,"GSE14580,GSE16879",54675
GSM364651,UCNR11_beforeT,GSM364651,Public on Nov 03 2009,Jan 26 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from UC non-responder before first infliximab treatment,Homo sapiens,9606,Colon,UC,No,Before first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from UC non-responder before first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM364nnn/GSM364651/suppl/GSM364651.CEL.gz,Reanalyzed by: GSE119087,"GSE14580,GSE16879",54675
GSM364652,UCNR12_beforeT,GSM364652,Public on Nov 03 2009,Jan 26 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from UC non-responder before first infliximab treatment,Homo sapiens,9606,Colon,UC,No,Before first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from UC non-responder before first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM364nnn/GSM364652/suppl/GSM364652.CEL.gz,Reanalyzed by: GSE119087,"GSE14580,GSE16879",54675
GSM364653,UCNR13_beforeT,GSM364653,Public on Nov 03 2009,Jan 26 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from UC non-responder before first infliximab treatment,Homo sapiens,9606,Colon,UC,No,Before first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from UC non-responder before first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM364nnn/GSM364653/suppl/GSM364653.CEL.gz,Reanalyzed by: GSE119087,"GSE14580,GSE16879",54675
GSM364654,UCNR14_beforeT,GSM364654,Public on Nov 03 2009,Jan 26 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from UC non-responder before first infliximab treatment,Homo sapiens,9606,Colon,UC,No,Before first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from UC non-responder before first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM364nnn/GSM364654/suppl/GSM364654.CEL.gz,Reanalyzed by: GSE119087,"GSE14580,GSE16879",54675
GSM364655,UCNR15_beforeT,GSM364655,Public on Nov 03 2009,Jan 26 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from UC non-responder before first infliximab treatment,Homo sapiens,9606,Colon,UC,No,Before first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from UC non-responder before first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM364nnn/GSM364655/suppl/GSM364655.CEL.gz,Reanalyzed by: GSE119087,"GSE14580,GSE16879",54675
GSM364656,UCNR16_beforeT,GSM364656,Public on Nov 03 2009,Jan 26 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from UC non-responder before first infliximab treatment,Homo sapiens,9606,Colon,UC,No,Before first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from UC non-responder before first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM364nnn/GSM364656/suppl/GSM364656.CEL.gz,Reanalyzed by: GSE119087,"GSE14580,GSE16879",54675
GSM422963,UCR1_afterT,GSM422963,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from UC responder after first infliximab treatment,Homo sapiens,9606,Colon,UC,Yes,After first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from UC responder after first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM422nnn/GSM422963/suppl/GSM422963.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM422965,UCR2_afterT,GSM422965,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from UC responder after first infliximab treatment,Homo sapiens,9606,Colon,UC,Yes,After first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from UC responder after first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM422nnn/GSM422965/suppl/GSM422965.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM422967,UCR3_afterT,GSM422967,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from UC responder after first infliximab treatment,Homo sapiens,9606,Colon,UC,Yes,After first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from UC responder after first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM422nnn/GSM422967/suppl/GSM422967.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM422969,UCR4_afterT,GSM422969,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from UC responder after first infliximab treatment,Homo sapiens,9606,Colon,UC,Yes,After first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from UC responder after first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM422nnn/GSM422969/suppl/GSM422969.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM422971,UCR5_afterT,GSM422971,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from UC responder after first infliximab treatment,Homo sapiens,9606,Colon,UC,Yes,After first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from UC responder after first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM422nnn/GSM422971/suppl/GSM422971.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM422973,UCR6_afterT,GSM422973,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from UC responder after first infliximab treatment,Homo sapiens,9606,Colon,UC,Yes,After first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from UC responder after first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM422nnn/GSM422973/suppl/GSM422973.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM422975,UCR7_afterT,GSM422975,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from UC responder after first infliximab treatment,Homo sapiens,9606,Colon,UC,Yes,After first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from UC responder after first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM422nnn/GSM422975/suppl/GSM422975.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM422977,UCR8_afterT,GSM422977,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from UC responder after first infliximab treatment,Homo sapiens,9606,Colon,UC,Yes,After first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from UC responder after first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM422nnn/GSM422977/suppl/GSM422977.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM422979,UCNR1_afterT,GSM422979,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from UC non-responder after first infliximab treatment,Homo sapiens,9606,Colon,UC,No,After first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from UC non-responder after first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM422nnn/GSM422979/suppl/GSM422979.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM422981,UCNR2_afterT,GSM422981,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from UC non-responder after first infliximab treatment,Homo sapiens,9606,Colon,UC,No,After first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from UC non-responder after first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM422nnn/GSM422981/suppl/GSM422981.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM422983,UCNR3_afterT,GSM422983,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from UC non-responder after first infliximab treatment,Homo sapiens,9606,Colon,UC,No,After first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from UC non-responder after first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM422nnn/GSM422983/suppl/GSM422983.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM422985,UCNR4_afterT,GSM422985,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from UC non-responder after first infliximab treatment,Homo sapiens,9606,Colon,UC,No,After first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from UC non-responder after first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM422nnn/GSM422985/suppl/GSM422985.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM422987,UCNR5_afterT,GSM422987,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from UC non-responder after first infliximab treatment,Homo sapiens,9606,Colon,UC,No,After first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from UC non-responder after first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM422nnn/GSM422987/suppl/GSM422987.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM422989,UCNR6_afterT,GSM422989,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from UC non-responder after first infliximab treatment,Homo sapiens,9606,Colon,UC,No,After first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from UC non-responder after first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM422nnn/GSM422989/suppl/GSM422989.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM422991,UCNR7_afterT,GSM422991,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from UC non-responder after first infliximab treatment,Homo sapiens,9606,Colon,UC,No,After first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from UC non-responder after first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM422nnn/GSM422991/suppl/GSM422991.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM422993,UCNR8_afterT,GSM422993,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from UC non-responder after first infliximab treatment,Homo sapiens,9606,Colon,UC,No,After first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from UC non-responder after first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM422nnn/GSM422993/suppl/GSM422993.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM422995,UCNR9_afterT,GSM422995,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from UC non-responder after first infliximab treatment,Homo sapiens,9606,Colon,UC,No,After first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from UC non-responder after first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM422nnn/GSM422995/suppl/GSM422995.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM422997,UCNR10_afterT,GSM422997,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from UC non-responder after first infliximab treatment,Homo sapiens,9606,Colon,UC,No,After first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from UC non-responder after first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM422nnn/GSM422997/suppl/GSM422997.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM422999,UCNR11_afterT,GSM422999,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from UC non-responder after first infliximab treatment,Homo sapiens,9606,Colon,UC,No,After first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from UC non-responder after first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM422nnn/GSM422999/suppl/GSM422999.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423001,UCNR12_afterT,GSM423001,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from UC non-responder after first infliximab treatment,Homo sapiens,9606,Colon,UC,No,After first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from UC non-responder after first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423001/suppl/GSM423001.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423003,UCNR13_afterT,GSM423003,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from UC non-responder after first infliximab treatment,Homo sapiens,9606,Colon,UC,No,After first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from UC non-responder after first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423003/suppl/GSM423003.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423005,UCNR14_afterT,GSM423005,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from UC non-responder after first infliximab treatment,Homo sapiens,9606,Colon,UC,No,After first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from UC non-responder after first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423005/suppl/GSM423005.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423007,UCNR15_afterT,GSM423007,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from UC non-responder after first infliximab treatment,Homo sapiens,9606,Colon,UC,No,After first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from UC non-responder after first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423007/suppl/GSM423007.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423009,UCNR16_afterT,GSM423009,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from UC non-responder after first infliximab treatment,Homo sapiens,9606,Colon,UC,No,After first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from UC non-responder after first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423009/suppl/GSM423009.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423010,CDcR1_beforeT,GSM423010,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from CDc responder before first infliximab treatment,Homo sapiens,9606,Colon,CD,Yes,Before first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from CDc responder before first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423010/suppl/GSM423010.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423011,CDcR1_afterT,GSM423011,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from CDc responder after first infliximab treatment,Homo sapiens,9606,Colon,CD,Yes,After first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from CDc responder after first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423011/suppl/GSM423011.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423012,CDcR2_beforeT,GSM423012,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from CDc responder before first infliximab treatment,Homo sapiens,9606,Colon,CD,Yes,Before first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from CDc responder before first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423012/suppl/GSM423012.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423013,CDcR3_beforeT,GSM423013,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from CDc responder before first infliximab treatment,Homo sapiens,9606,Colon,CD,Yes,Before first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from CDc responder before first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423013/suppl/GSM423013.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423014,CDcR3_afterT,GSM423014,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from CDc responder after first infliximab treatment,Homo sapiens,9606,Colon,CD,Yes,After first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from CDc responder after first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423014/suppl/GSM423014.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423015,CDcR4_beforeT,GSM423015,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from CDc responder before first infliximab treatment,Homo sapiens,9606,Colon,CD,Yes,Before first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from CDc responder before first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423015/suppl/GSM423015.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423016,CDcR4_afterT,GSM423016,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from CDc responder after first infliximab treatment,Homo sapiens,9606,Colon,CD,Yes,After first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from CDc responder after first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423016/suppl/GSM423016.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423017,CDcR5_beforeT,GSM423017,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from CDc responder before first infliximab treatment,Homo sapiens,9606,Colon,CD,Yes,Before first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from CDc responder before first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423017/suppl/GSM423017.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423018,CDcR5_afterT,GSM423018,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from CDc responder after first infliximab treatment,Homo sapiens,9606,Colon,CD,Yes,After first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from CDc responder after first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423018/suppl/GSM423018.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423019,CDcR6_beforeT,GSM423019,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from CDc responder before first infliximab treatment,Homo sapiens,9606,Colon,CD,Yes,Before first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from CDc responder before first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423019/suppl/GSM423019.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423020,CDcR6_afterT,GSM423020,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from CDc responder after first infliximab treatment,Homo sapiens,9606,Colon,CD,Yes,After first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from CDc responder after first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423020/suppl/GSM423020.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423021,CDcR7_beforeT,GSM423021,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from CDc responder before first infliximab treatment,Homo sapiens,9606,Colon,CD,Yes,Before first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from CDc responder before first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423021/suppl/GSM423021.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423022,CDcR7_afterT,GSM423022,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from CDc responder after first infliximab treatment,Homo sapiens,9606,Colon,CD,Yes,After first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from CDc responder after first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423022/suppl/GSM423022.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423023,CDcR8_beforeT,GSM423023,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from CDc responder before first infliximab treatment,Homo sapiens,9606,Colon,CD,Yes,Before first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from CDc responder before first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423023/suppl/GSM423023.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423024,CDcR8_afterT,GSM423024,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from CDc responder after first infliximab treatment,Homo sapiens,9606,Colon,CD,Yes,After first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from CDc responder after first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423024/suppl/GSM423024.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423025,CDcR9_beforeT,GSM423025,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from CDc responder before first infliximab treatment,Homo sapiens,9606,Colon,CD,Yes,Before first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from CDc responder before first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423025/suppl/GSM423025.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423026,CDcR9_afterT,GSM423026,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from CDc responder after first infliximab treatment,Homo sapiens,9606,Colon,CD,Yes,After first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from CDc responder after first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423026/suppl/GSM423026.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423027,CDcR10_beforeT,GSM423027,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from CDc responder before first infliximab treatment,Homo sapiens,9606,Colon,CD,Yes,Before first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from CDc responder before first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423027/suppl/GSM423027.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423028,CDcR10_afterT,GSM423028,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from CDc responder after first infliximab treatment,Homo sapiens,9606,Colon,CD,Yes,After first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from CDc responder after first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423028/suppl/GSM423028.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423029,CDcR11_beforeT,GSM423029,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from CDc responder before first infliximab treatment,Homo sapiens,9606,Colon,CD,Yes,Before first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from CDc responder before first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423029/suppl/GSM423029.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423030,CDcR11_afterT,GSM423030,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from CDc responder after first infliximab treatment,Homo sapiens,9606,Colon,CD,Yes,After first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from CDc responder after first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423030/suppl/GSM423030.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423031,CDcR12_beforeT,GSM423031,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from CDc responder before first infliximab treatment,Homo sapiens,9606,Colon,CD,Yes,Before first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from CDc responder before first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423031/suppl/GSM423031.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423032,CDcR12_afterT,GSM423032,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from CDc responder after first infliximab treatment,Homo sapiens,9606,Colon,CD,Yes,After first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from CDc responder after first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423032/suppl/GSM423032.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423033,CDcNR1_beforeT,GSM423033,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from CDc non-responder before first infliximab treatment,Homo sapiens,9606,Colon,CD,No,Before first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from CDc non-responder before first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423033/suppl/GSM423033.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423034,CDcNR1_afterT,GSM423034,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from CDc non-responder after first infliximab treatment,Homo sapiens,9606,Colon,CD,No,After first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from CDc non-responder after first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423034/suppl/GSM423034.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423035,CDcNR2_beforeT,GSM423035,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from CDc non-responder before first infliximab treatment,Homo sapiens,9606,Colon,CD,No,Before first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from CDc non-responder before first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423035/suppl/GSM423035.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423036,CDcNR2_afterT,GSM423036,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from CDc non-responder after first infliximab treatment,Homo sapiens,9606,Colon,CD,No,After first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from CDc non-responder after first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423036/suppl/GSM423036.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423037,CDcNR3_beforeT,GSM423037,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from CDc non-responder before first infliximab treatment,Homo sapiens,9606,Colon,CD,No,Before first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from CDc non-responder before first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423037/suppl/GSM423037.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423038,CDcNR3_afterT,GSM423038,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from CDc non-responder after first infliximab treatment,Homo sapiens,9606,Colon,CD,No,After first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from CDc non-responder after first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423038/suppl/GSM423038.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423039,CDcNR4_beforeT,GSM423039,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from CDc non-responder before first infliximab treatment,Homo sapiens,9606,Colon,CD,No,Before first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from CDc non-responder before first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423039/suppl/GSM423039.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423040,CDcNR4_afterT,GSM423040,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from CDc non-responder after first infliximab treatment,Homo sapiens,9606,Colon,CD,No,After first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from CDc non-responder after first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423040/suppl/GSM423040.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423041,CDcNR5_beforeT,GSM423041,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from CDc non-responder before first infliximab treatment,Homo sapiens,9606,Colon,CD,No,Before first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from CDc non-responder before first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423041/suppl/GSM423041.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423042,CDcNR5_afterT,GSM423042,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from CDc non-responder after first infliximab treatment,Homo sapiens,9606,Colon,CD,No,After first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from CDc non-responder after first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423042/suppl/GSM423042.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423043,CDcNR6_beforeT,GSM423043,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from CDc non-responder before first infliximab treatment,Homo sapiens,9606,Colon,CD,No,Before first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from CDc non-responder before first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423043/suppl/GSM423043.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423044,CDcNR6_afterT,GSM423044,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from CDc non-responder after first infliximab treatment,Homo sapiens,9606,Colon,CD,No,After first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from CDc non-responder after first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423044/suppl/GSM423044.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423045,CDcNR7_beforeT,GSM423045,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from CDc non-responder before first infliximab treatment,Homo sapiens,9606,Colon,CD,No,Before first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from CDc non-responder before first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423045/suppl/GSM423045.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423046,CDcNR7_afterT,GSM423046,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Colonic mucosal biopsy from CDc non-responder after first infliximab treatment,Homo sapiens,9606,Colon,CD,No,After first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Colonic mucosal gene expression data from CDc non-responder after first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423046/suppl/GSM423046.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423047,IL1,GSM423047,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Ileal mucosal biopsy from control individual,Homo sapiens,9606,Ileum,Control,Not applicable,Not applicable,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Ileal mucosal gene expression data from control individual,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423047/suppl/GSM423047.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423048,IL2,GSM423048,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Ileal mucosal biopsy from control individual,Homo sapiens,9606,Ileum,Control,Not applicable,Not applicable,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Ileal mucosal gene expression data from control individual,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423048/suppl/GSM423048.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423049,IL3,GSM423049,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Ileal mucosal biopsy from control individual,Homo sapiens,9606,Ileum,Control,Not applicable,Not applicable,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Ileal mucosal gene expression data from control individual,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423049/suppl/GSM423049.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423050,IL4,GSM423050,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Ileal mucosal biopsy from control individual,Homo sapiens,9606,Ileum,Control,Not applicable,Not applicable,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Ileal mucosal gene expression data from control individual,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423050/suppl/GSM423050.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423051,IL5,GSM423051,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Ileal mucosal biopsy from control individual,Homo sapiens,9606,Ileum,Control,Not applicable,Not applicable,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Ileal mucosal gene expression data from control individual,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423051/suppl/GSM423051.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423052,IL6,GSM423052,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Ileal mucosal biopsy from control individual,Homo sapiens,9606,Ileum,Control,Not applicable,Not applicable,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Ileal mucosal gene expression data from control individual,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423052/suppl/GSM423052.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423053,CDiR1_beforeT,GSM423053,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Ileal mucosal biopsy from CDi responder before first infliximab treatment,Homo sapiens,9606,Ileum,CD,Yes,Before first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Ileal mucosal gene expression data from CDi responder before first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423053/suppl/GSM423053.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423054,CDiR1_afterT,GSM423054,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Ileal mucosal biopsy from CDi responder after first infliximab treatment,Homo sapiens,9606,Ileum,CD,Yes,After first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Ileal mucosal gene expression data from CDi responder after first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423054/suppl/GSM423054.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423055,CDiR2_beforeT,GSM423055,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Ileal mucosal biopsy from CDi responder before first infliximab treatment,Homo sapiens,9606,Ileum,CD,Yes,Before first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Ileal mucosal gene expression data from CDi responder before first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423055/suppl/GSM423055.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423056,CDiR2_afterT,GSM423056,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Ileal mucosal biopsy from CDi responder after first infliximab treatment,Homo sapiens,9606,Ileum,CD,Yes,After first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Ileal mucosal gene expression data from CDi responder after first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423056/suppl/GSM423056.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423057,CDiR3_beforeT,GSM423057,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Ileal mucosal biopsy from CDi responder before first infliximab treatment,Homo sapiens,9606,Ileum,CD,Yes,Before first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Ileal mucosal gene expression data from CDi responder before first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423057/suppl/GSM423057.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423058,CDiR3_afterT,GSM423058,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Ileal mucosal biopsy from CDi responder after first infliximab treatment,Homo sapiens,9606,Ileum,CD,Yes,After first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Ileal mucosal gene expression data from CDi responder after first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423058/suppl/GSM423058.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423059,CDiR4_beforeT,GSM423059,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Ileal mucosal biopsy from CDi responder before first infliximab treatment,Homo sapiens,9606,Ileum,CD,Yes,Before first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Ileal mucosal gene expression data from CDi responder before first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423059/suppl/GSM423059.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423060,CDiR4_afterT,GSM423060,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Ileal mucosal biopsy from CDi responder after first infliximab treatment,Homo sapiens,9606,Ileum,CD,Yes,After first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Ileal mucosal gene expression data from CDi responder after first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423060/suppl/GSM423060.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423061,CDiR5_beforeT,GSM423061,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Ileal mucosal biopsy from CDi responder before first infliximab treatment,Homo sapiens,9606,Ileum,CD,Yes,Before first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Ileal mucosal gene expression data from CDi responder before first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423061/suppl/GSM423061.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423062,CDiR5_afterT,GSM423062,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Ileal mucosal biopsy from CDi responder after first infliximab treatment,Homo sapiens,9606,Ileum,CD,Yes,After first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Ileal mucosal gene expression data from CDi responder after first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423062/suppl/GSM423062.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423063,CDiR6_beforeT,GSM423063,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Ileal mucosal biopsy from CDi responder before first infliximab treatment,Homo sapiens,9606,Ileum,CD,Yes,Before first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Ileal mucosal gene expression data from CDi responder before first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423063/suppl/GSM423063.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423064,CDiR6_afterT,GSM423064,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Ileal mucosal biopsy from CDi responder after first infliximab treatment,Homo sapiens,9606,Ileum,CD,Yes,After first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Ileal mucosal gene expression data from CDi responder after first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423064/suppl/GSM423064.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423065,CDiR7_beforeT,GSM423065,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Ileal mucosal biopsy from CDi responder before first infliximab treatment,Homo sapiens,9606,Ileum,CD,Yes,Before first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Ileal mucosal gene expression data from CDi responder before first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423065/suppl/GSM423065.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423066,CDiR7_afterT,GSM423066,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Ileal mucosal biopsy from CDi responder after first infliximab treatment,Homo sapiens,9606,Ileum,CD,Yes,After first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Ileal mucosal gene expression data from CDi responder after first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423066/suppl/GSM423066.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423067,CDiR8_beforeT,GSM423067,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Ileal mucosal biopsy from CDi responder before first infliximab treatment,Homo sapiens,9606,Ileum,CD,Yes,Before first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Ileal mucosal gene expression data from CDi responder before first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423067/suppl/GSM423067.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423068,CDiR8_afterT,GSM423068,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Ileal mucosal biopsy from CDi responder after first infliximab treatment,Homo sapiens,9606,Ileum,CD,Yes,After first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Ileal mucosal gene expression data from CDi responder after first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423068/suppl/GSM423068.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423069,CDiNR1_beforeT,GSM423069,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Ileal mucosal biopsy from CDi non-responder before first infliximab treatment,Homo sapiens,9606,Ileum,CD,No,Before first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Ileal mucosal gene expression data from CDi non-responder before first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423069/suppl/GSM423069.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423070,CDiNR1_afterT,GSM423070,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Ileal mucosal biopsy from CDi non-responder after first infliximab treatment,Homo sapiens,9606,Ileum,CD,No,After first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Ileal mucosal gene expression data from CDi non-responder after first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423070/suppl/GSM423070.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423071,CDiNR2_beforeT,GSM423071,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Ileal mucosal biopsy from CDi non-responder before first infliximab treatment,Homo sapiens,9606,Ileum,CD,No,Before first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Ileal mucosal gene expression data from CDi non-responder before first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423071/suppl/GSM423071.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423072,CDiNR2_afterT,GSM423072,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Ileal mucosal biopsy from CDi non-responder after first infliximab treatment,Homo sapiens,9606,Ileum,CD,No,After first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Ileal mucosal gene expression data from CDi non-responder after first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423072/suppl/GSM423072.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423073,CDiNR3_beforeT,GSM423073,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Ileal mucosal biopsy from CDi non-responder before first infliximab treatment,Homo sapiens,9606,Ileum,CD,No,Before first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Ileal mucosal gene expression data from CDi non-responder before first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423073/suppl/GSM423073.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423074,CDiNR3_afterT,GSM423074,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Ileal mucosal biopsy from CDi non-responder after first infliximab treatment,Homo sapiens,9606,Ileum,CD,No,After first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Ileal mucosal gene expression data from CDi non-responder after first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423074/suppl/GSM423074.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423075,CDiNR4_beforeT,GSM423075,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Ileal mucosal biopsy from CDi non-responder before first infliximab treatment,Homo sapiens,9606,Ileum,CD,No,Before first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Ileal mucosal gene expression data from CDi non-responder before first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423075/suppl/GSM423075.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423076,CDiNR4_afterT,GSM423076,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Ileal mucosal biopsy from CDi non-responder after first infliximab treatment,Homo sapiens,9606,Ileum,CD,No,After first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Ileal mucosal gene expression data from CDi non-responder after first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423076/suppl/GSM423076.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423077,CDiNR5_beforeT,GSM423077,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Ileal mucosal biopsy from CDi non-responder before first infliximab treatment,Homo sapiens,9606,Ileum,CD,No,Before first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Ileal mucosal gene expression data from CDi non-responder before first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423077/suppl/GSM423077.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423078,CDiNR5_afterT,GSM423078,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Ileal mucosal biopsy from CDi non-responder after first infliximab treatment,Homo sapiens,9606,Ileum,CD,No,After first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Ileal mucosal gene expression data from CDi non-responder after first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423078/suppl/GSM423078.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423079,CDiNR6_beforeT,GSM423079,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Ileal mucosal biopsy from CDi non-responder before first infliximab treatment,Homo sapiens,9606,Ileum,CD,No,Before first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Ileal mucosal gene expression data from CDi non-responder before first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423079/suppl/GSM423079.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423080,CDiNR6_afterT,GSM423080,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Ileal mucosal biopsy from CDi non-responder after first infliximab treatment,Homo sapiens,9606,Ileum,CD,No,After first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Ileal mucosal gene expression data from CDi non-responder after first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423080/suppl/GSM423080.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423081,CDiNR7_beforeT,GSM423081,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Ileal mucosal biopsy from CDi non-responder before first infliximab treatment,Homo sapiens,9606,Ileum,CD,No,Before first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Ileal mucosal gene expression data from CDi non-responder before first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423081/suppl/GSM423081.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423082,CDiNR7_afterT,GSM423082,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Ileal mucosal biopsy from CDi non-responder after first infliximab treatment,Homo sapiens,9606,Ileum,CD,No,After first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Ileal mucosal gene expression data from CDi non-responder after first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423082/suppl/GSM423082.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423083,CDiNR8_beforeT,GSM423083,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Ileal mucosal biopsy from CDi non-responder before first infliximab treatment,Homo sapiens,9606,Ileum,CD,No,Before first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Ileal mucosal gene expression data from CDi non-responder before first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423083/suppl/GSM423083.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423084,CDiNR8_afterT,GSM423084,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Ileal mucosal biopsy from CDi non-responder after first infliximab treatment,Homo sapiens,9606,Ileum,CD,No,After first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Ileal mucosal gene expression data from CDi non-responder after first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423084/suppl/GSM423084.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423085,CDiNR9_beforeT,GSM423085,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Ileal mucosal biopsy from CDi non-responder before first infliximab treatment,Homo sapiens,9606,Ileum,CD,No,Before first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Ileal mucosal gene expression data from CDi non-responder before first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423085/suppl/GSM423085.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423086,CDiNR9_afterT,GSM423086,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Ileal mucosal biopsy from CDi non-responder after first infliximab treatment,Homo sapiens,9606,Ileum,CD,No,After first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Ileal mucosal gene expression data from CDi non-responder after first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423086/suppl/GSM423086.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423087,CDiNR10_beforeT,GSM423087,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Ileal mucosal biopsy from CDi non-responder before first infliximab treatment,Homo sapiens,9606,Ileum,CD,No,Before first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Ileal mucosal gene expression data from CDi non-responder before first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423087/suppl/GSM423087.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
GSM423088,CDiNR10_afterT,GSM423088,Public on Nov 03 2009,Jun 29 2009,Aug 28 2018,RNA,1,Ileal mucosal biopsy from CDi non-responder after first infliximab treatment,Homo sapiens,9606,Ileum,CD,No,After first infliximab treatment,total RNA,"Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Benelux B.V.), according to the manufacturerâ€™s instructions. The total RNA integrity and quantity were assessed with the Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and Nanodrop ND-1000 spectrophotometer (Nanodrop technologies), respectively.",biotin,"Total RNA (2 Âµg) was reverse-transcribed into cDNA using the SuperScript Choice System (Invitrogen, Carlsbad, CA, USA) with oligo-dT primers containing a T7 RNA polymerase promoter site. cDNA was in vitro transcribed to cRNA and biotin labeled using the IVT labeling kit (Affymetrix, Santa Clara, CA, USA), according to Affymetrix expression analysis technical manual 701021Rev.5. Biotinylated cRNA was purified and fragmented. The quality of labeled and fragmented cRNA, respectively, was assessed with the Agilent 2100 Bioanalyzer.",Fragmented cRNA (15 Âµg) was hybridized overnight to the Human Genome U133 Plus 2.0 Array (Affymetrix).,The arrays were washed and stained with streptavidin-phycoerytrin on an automated Fluidics Station (Affymetrix) and scanned on the Affymetrix 3000 GeneScanner.,Ileal mucosal gene expression data from CDi non-responder after first infliximab treatment,"The resulting image files (.dat files) were analyzed using Affymetrix GCOS software, and intensity values for each probe cell (.cel file) were calculated. Intensity values were scaled to an average of 150 per array according to the method of global scaling provided in the GCOS.",GPL570,"Ingrid,,Arijs",ingrid.arijs@med.kuleuven.be,TARGID - IBD Leuven,Clinical and Experimental Medicine,KULeuven,Herestraat 49,Leuven,3000,Belgium,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM423nnn/GSM423088/suppl/GSM423088.CEL.gz,Reanalyzed by: GSE119087,GSE16879,54675
